A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)
A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)
Sponsor: GlaxoSmithKline
Listed as NCT02076386, this observational or N/A phase trial focuses on Infection, Human Immunodeficiency Virus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 11 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2018 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Jul 2018 — Sep 2018 [monthly]
Completed
-
Jun 2018 — Jul 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jul 2017 — Nov 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Berlin, Germany , Bochum, Germany , Chemnitz, Germany , Cologne, Germany , Dortmund, Germany , Düsseldorf, Germany , Frankfurt am Main, Germany , Freiburg im Breisgau, Germany , Fürth, Germany and 12 more locations